Cardiac transplantation for endstage heart disease

Heart and Vessels

Volumn 12, Issue SUPPL. 12, 1997, Pages 23-27

  Argenziano, Michael ^a,b   Michler, Robert E ^a   Rose, Eric A ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b Milstein Hospital   (United States)

Author keywords

Heart failure; Heart transplantation; Immunosuppression

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; OKT 3; STEROID; THYMOCYTE ANTIBODY;

ANGINA PECTORIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; GRAFT INFECTION; GRAFT REJECTION; HEALTH CARE COST; HEART FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEART TUMOR; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISEASE; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; SURVIVAL RATE; COST; ECONOMICS; HEART DISEASE; POSTOPERATIVE COMPLICATION; REVIEW; TREATMENT OUTCOME;

COSTS AND COST ANALYSIS; GRAFT REJECTION; HEART DISEASES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; LYMPHOPROLIFERATIVE DISORDERS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME;

EID: 0031283319     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Barnard CN (1967) The operation. S Afr Med J 41:1271-1274
2. White DJG (1993) Immunosuppression for heart transplantation. Br J Biomed Sci 50:277-283
3. Hosenpud JD (1994) The Registry of the International Society for Heart and Lung Transplantation: Eleventh official report - 1994. J Heart Lung Transplant 13:561-570
4. Kaye MP (1992) The Registry of the International Society of Heart and Lung Transplantation: Ninth official report -1992. J Heart Lung Transplant 11:599-606
5. Mancini DM, Eisen H, Kussmaul W, et al. (1991) Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83:778-786
6. Sarris GE, Moore KA, Schroeder JS, et al. (1994) Cardiac transplantation: The Stanford experience in the cyclosporine era. J Thorac Cardiovasc Surg 108:240-252
7. Oz MC, Argenziano M, Catanese KA, et al. (1997) Bridge experience with long-term implantable left ventricular assist devices: Are they an alternative to transplantation? Circulation 95:1844-1852
8. Michler RE, Chen JM, Mancini DM, Reemtsma K, Rose EA (1993) Sixteen years of cardiac transplantation: The Columbia-Presbyterian Medical Center experience 1977-1993. Clin Transpl 109-118
9. Caves PK, Stinson EB, Billingham ME, et al. (1973) Diagnosis of human cardiac allograft rejection by serial cardiac biopsy. J Thorac Cardiovasc Surg 66:461-466
10. Gao SZ, Schroeder JS, Alderman EL, et al. (1989) Prevalence of accelerated coronary artery disease in heart transplant survivors: Comparison of cyclosporine and azathioprine regimens. Circulation 80 (Suppl):III100-III105
11. Uretsky BF, Murali S, Reddy PS, et al. (1987) Development of coronary artery disease in cardiac transplant recipients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 76:827-834
12. Billingham ME (1992) Histopathology of graft coronary disease. J Heart Lung Transplant 3:538-544
13. Griepp RB, Stinson EB, Bieber CD, et al. (1977) Control of graft atherosclerosis in human heart transplant recipients. Surgery 81:262-269
14. Schroeder JS, Gao SZ, Alderman EL, et al. (1993) A preliminary study of diltiazem in the prevention of coronary artery disease in heart transplant recipients. N Engl J Med 328:164-170
15. Votapka TV, Swartz MT, Reedy JE, et al. (1995) Heart transplantation charges: Status 1 versus status 2 patients. J Heart Lung Transplant 14:366-372
16. Penn I (1986) Cancer is a complication of severe immunosuppression. Surg Gynecol Obstet 162:603-610
17. Chen JM, Barr ML, Chadburn A, et al. (1993) Management of lymphoproliferative disorders after cardiac transplantation. Ann Thorac Surg 56:527-538
18. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. (1982) Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 306:913-918
19. Reemtsma K, Berland G, Merrill J, et al. (1992) Evaluation of surgical procedures: Changing patterns of patient selection and costs in heart transplantation. J Thorac Cardiovasc Surg 104:1308-1313
20. Ochai T, Nkajima K,.Susuki T, et al. (1987) Effects of a new immunosuppressive agent FK506 on heterotopic cardiac allotransplantation in rats. Transplant Proc 19:1284-1287
21. Kirklin JK, Bourge RC, Naftel DC, et al. (1994) Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): Initial clinical experience. J Heart Lung Transplant 13:444-450
22. Lavee J, Kormos RL, Duquesnoy RJ, et al. (1991) Influence of panel-reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 10:921-930